27.01.2013 Views

DERGİSİ TIPDERGİSİ - DNT ORTADOĞU YAYINCILIK :: Anasayfa

DERGİSİ TIPDERGİSİ - DNT ORTADOĞU YAYINCILIK :: Anasayfa

DERGİSİ TIPDERGİSİ - DNT ORTADOĞU YAYINCILIK :: Anasayfa

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Is Percentage Of Cancer Positive Cores In Prostate Biopsy Useful For Predicting The<br />

Changes In Gleason Scores After Radical Prostatectomy?<br />

Introduction<br />

Radical prostatectomy (RP), remains to be the treatment<br />

of choice for the patients with clinically localized prostate<br />

cancer and a life-expectancy of at least 10 years, due to<br />

its continously refined surgical outcomes and decreasing<br />

morbidity and mortality rates. Local recurrence-free survival<br />

rates of 83% and 75% were reported after RP for<br />

10 and 15 years, respectively (1). Prognostic factors after<br />

RP include baseline PSA level, clinical stage, biopsy<br />

Gleason score, postoperative Gleason score and pathological<br />

stage (2-4). It has been demonstrated in various studies<br />

that prostatectomy Gleason score is the most important<br />

prognostic factor for biochemical recurrence after RP<br />

(5, 6). Higher prostatectomy gleason score is associated<br />

with higher postoperative biochemical recurrence and low<br />

cancer-specific survival rates(7). On the other hand, it was<br />

reported that although the biopsy Gleason score remained<br />

unchanged after RP in 31-63% of the patients, it increased<br />

in 35 to 44% of them (8-10). These findings suggest that<br />

a pre-operative low-risk patient for biochemical failure<br />

and cancer-specific survival according to biopsy Gleason<br />

score may be in fact, a high-risk patient with respect to<br />

the RP gleason score. Considering the points mentioned<br />

above, preoperative prediction of the patients who are at<br />

the risk of Gleason score increase after RP may contribute<br />

the overall outcome of the definitive therapy.<br />

The association between the Gleason score increase after<br />

RP and percentage of positive biopsy cores was evaluated<br />

in this study.<br />

Material and Methods<br />

One hundred and ninety-five patients who underwent RP<br />

for clinically localized prostate cancer between January<br />

1997 and may 2008 were included in the study. Clinical<br />

and pathological records of the patients were evaluated retrospectively.<br />

Patients with a history of previous radiation<br />

or hormonal therapy (n=7), with 4ng/ml . PPC was obtained by dividing<br />

the number of cancer positive cores to the total number of<br />

biopsy cores. The total and free PSA levels were measured<br />

with monoclonal tandem assays using various kits in time.<br />

Histological grading of biopsy and RP specimens were<br />

made according to the Gleason grading system (11).<br />

50 ORTADOGU MEDICAL JOURNAL 4 (2): 49- 52 2012<br />

Gleason score increase and decrease were defined as<br />

“higher” and “lower than biopsy” RP scores, respectively.<br />

Clinical and pathological staging were performed according<br />

to the 2002 TNM classification.<br />

Patients were followed every 3 months first year, every 6<br />

months for the next 5 years and annually afterwards, with<br />

DRE, PSA and/or bone scan. Two consecutive PSA levels<br />

≥0.2ng/ml were defined as biochemical failure.<br />

Data were analyzed using SPSS software v11.5. Cathegorical<br />

data were presented as the number and percentage of<br />

the patients whereas continous variables were expressed as<br />

mean±standard deviation. The differences between independent<br />

groups regarding continous variables were evaluated<br />

by Kruskal-Wallis test. For categorical comparisons<br />

Chi-square test was used. P values lower than 0.05 were<br />

considered as statistically significant.<br />

Results<br />

The mean age and mean baseline PSA values of the patients<br />

were 62.9±5.9 years and 11.4±9.6ng/ml, respectively. Preoperative<br />

clinical and pathological data of the patients are<br />

Table 1: Preoperative clinical and pathological data<br />

Mean Age (Years) 62.9±5.9<br />

Mean Baseline PSA (ng/ml) 11.4±9.6<br />

Baseline PSA<br />

n %<br />

15 ng/ml<br />

31 18.9<br />

Mean Prostate Volume (ml) 46.9±23.7<br />

Mean biopsy Gleason score 5.3±1.6<br />

Biopsy Gleason score<br />

n %<br />

2-4<br />

44 26.8<br />

5-7<br />

109 66.5<br />

8-10<br />

11 6.7<br />

Clinical stage<br />

n %<br />

T1a<br />

3 1.8<br />

T1b<br />

15 9.1<br />

T1c<br />

71 43.3<br />

T2a<br />

37 22.6<br />

T2b<br />

29 17.7<br />

T2c<br />

9 5.5<br />

Mean Number of biopsy cores 9.3±1.3<br />

Mean Number of positive biopsy cores 3.5±2.3<br />

Mean percentage of positive biopsy cores 0.38±0.25<br />

Percentage of positive biopsy cores n %<br />

≤0.20<br />

47 32.2<br />

0.21-0.40<br />

46 31.5<br />

0.41-0.60<br />

25 17.1<br />

≥0.61<br />

28 19.2

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!